sumifilam
Jump to navigation
Jump to search
Indications
- investigational agent for treatment of Alzheimer's disease
Dosage
- 50 mg or 100 mg BID
Mechanism of action
- binds to filamin A Clinical trials.
- phase 2b trial[1]
- improves entire panel of validated biomarkers
- improves episodic memory & spatial working memory vs placebo (46-17%)
More general terms
References
- ↑ 1.0 1.1 Cassava Sciences. Sept 14, 2020 Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer's Disease. https://www.globenewswire.com/news-release/2020/09/14/2092861/0/en/Cassava-Sciences-Announces-Final-Results-of-a-Phase-2b-Clinical-Study-of-Sumifilam-in-Patients-with-Alzheimer-s-Disease.html